Cancers

Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

Myeloid malignancies are clonal hematopoietic disorders characterized by the presence of mutations in hematopoietic progenitors. The application of modern genome sequencing has provided clues to identify novel mutated gene pathways and their roles in disease pathogenesis. Computer science has created the possibility to build algorithms and bioinformatics tools to incorporate a variety of genomic information possibly leading to improvement in the selection of therapeutics in the near future.

This special issue is open to original research articles and reviews on the scope of genetics and genomics of myeloid malignancies. Submissions on artificial intelligence and novel computational methods on genetics features of myeloid malignancies is highly encouraged.

Dr. Valeria Visconte
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

myeloid malignancies
genetics
genomics
artificial intelligence
novel computational methods

Published Papers (2 papers)

Download All Papers

Editorial

Jump to: Review

5 pages, 596 KiB

Open AccessEditorial

The Heterogeneous Complexity of Myeloid Neoplasm: Multi-Level Approaches to Study the Disease

by Hussein Awada and Valeria Visconte

Cancers 2023, 15(5), 1449; https://doi.org/10.3390/cancers15051449 - 24 Feb 2023

Viewed by 1116

Abstract

Myeloid neoplasms (MNs) include a spectrum of bone marrow malignancies that result from the clonal expansion and arrest of differentiation of myeloid progenitor cells [...] Full article

(This article belongs to the Special Issue Updates on the Genetics of Myeloid Malignancies)

► Show Figures

Figure 1

Review

Jump to: Editorial

18 pages, 1866 KiB

Open AccessReview

Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives

by Olisaemeka Ogbue, Serhan Unlu, Gogo-Ogute Ibodeng, Abhay Singh, Arda Durmaz, Valeria Visconte and John C. Molina

Cancers 2023, 15(9), 2477; https://doi.org/10.3390/cancers15092477 - 26 Apr 2023

Cited by 2 | Viewed by 2194

Abstract

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a previously challenging leukemic cell concentration. A major shortcoming of NGS techniques is the inability to discriminate nonleukemic clonal hematopoiesis. In addition, risk assessment and prognostication become more complicated after hematopoietic stem-cell transplantation (HSCT) due to genotypic drift. To address this, newer sequencing techniques have been developed, leading to more prospective and randomized clinical trials aiming to demonstrate the prognostic utility of single-cell next-generation sequencing in predicting patient outcomes following HSCT. This review discusses the use of single-cell DNA genomics in MRD assessment for AML/MDS, with an emphasis on the HSCT time period, including the challenges with current technologies. We also touch on the potential benefits of single-cell RNA sequencing and analysis of accessible chromatin, which generate high-dimensional data at the cellular resolution for investigational purposes, but not currently used in the clinical setting. Full article

(This article belongs to the Special Issue Updates on the Genetics of Myeloid Malignancies)

► Show Figures